Cabiralizumab ELISA Kit|Cabiralizumab ELISA试剂盒(靶标：)
- 货号：RB9TDY035018
- 价格：面议
- 点击：402
产品介绍
产品参数
| 应用 | ELISA |
|---|---|
| 检测方法 | Colorimetric |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 样本类型 | Plasma, Serum |
| 检测类型 | Quantitative |
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 运输条件 | 2-8 ℃ |
| 登录号 | P07333 |
| 背景信息 | Cabiralizumab (FPA008) is a humanized monoclonal antibody directed against colony stimulating factor-1 receptor (CSF1R), which is a member of the CSF1/PDGF receptor family of tyrosine-protein kinases. The developers of cabiralizumab including Apexigen, Bristol-Myers Squibb, Five Prime Therapeutics, University of Chicago and Yale University. Although it is reported to be designed for the treatment of tenosynovial giant cell tumor, the studies of treatment for pancreatic cancer, pigmented villonodular synovitis, malignant melanoma, non-small cell lung cancer, renal cell carcinoma and solid tumors also have been reported to be undergoing. The trails of pancreatic cancer and pigmented villonodular synovitis are in Phase II, while others are in Phase I. Orphan designation of cabiralizumab had been granted in the United States and European Commission for the treatment of pigmented villonodular synovitis. |
| 别名 | FPA-008, , 1613144-80-1 |
| 备注 | For Research Use Only. |
相关产品: